After several months of investigation, the U.S. Food and Drug Administration (FDA) announced that manufacturers of over-the-counter and prescription drugs containing ranitidine, such as Zantac, must immediately pull their products from the market. The FDA’s announcement comes after researchers discovered that many of these drugs contain unsafe levels of a contaminant, commonly referred to as NDMA. New Hampshire individuals who suffered injuries after consuming an unsafe medication, such as Zantac, may have a claim for damages under the state’s product liability laws.
Despite numerous studies indicating the link between ranitidine and cancer, for years, doctors and pharmacists have recommended these drugs for heartburn, stomach pains, and gastrointestinal issues. Moreover, evidence suggests that to protect their financial interest, some pharmaceutical companies concealed the link between cancer and the products for several years.
The FDA began conducting more extensive preliminary testing of the products’ NDMA levels after an online retailer alerted the agency of the extremely high levels of the cancer-causing agent in their products. Although, many food and drinks contain small levels of NDMA, the agency warns that the drugs in issue contain levels that are unsafe for human consumption. Some of the samples they tested contained insignificant levels of the contaminant; however, others had significant levels of the impurity. They discovered that the impurity level increased when the product was left out at higher temperatures for more extended periods.